Brain Disease Device And Software Market Report 2026

Brain Disease Device And Software Market Overview

• Brain Disease Device And Software market size has reached to $15.59 billion in 2025 • Expected to grow to $25.21 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Increasing Prevalence Of Neurological Disorders Fueling The Growth Of The Market Due To Aging Population And Rising Disease Burden • Market Trend: AI-Driven Solutions Transforming Brain Disease Detection And Monitoring • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Brain Disease Device And Software Market?

Brain disease device and software refers to specialized medical tools and digital applications designed to diagnose, monitor, and treat neurological disorders and brain-related conditions. These devices and software aid in detecting abnormalities, guiding therapy, and managing diseases. Their primary purpose is to improve patient outcomes by enabling accurate assessment, personalized treatment, and continuous monitoring of brain health. The main types of brain disease device and software are brain disease devices and brain disease software. A brain disease device refers to a medical device designed to diagnose, monitor, treat, or support the rehabilitation of neurological disorders affecting brain function. These devices utilize various technologies, including wearable technology, telemedicine solutions, artificial intelligence and machine learning, mobile health applications, and neuroimaging technologies. These are used for various applications such as Alzheimer's disease, Parkinson's disease, epilepsy, and other applications, serving a wide range of end users, including hospitals and clinics, home care settings, rehabilitation centers, research and academic institutions, and diagnostic laboratories.

What Is The Brain Disease Device And Software Market Growth Forecast?

The brain disease device and software market size is expected to see rapid growth in the next few years. It will grow to $25.21 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to advancements in wearable and ai-enabled brain disease devices, increased investment in neurorehabilitation technologies, expansion of home care and remote monitoring solutions, rising demand for brain data management software, growing research in neuroinformatics and cognitive assessment technologies. Major trends in the forecast period include rising adoption of neurostimulation and brain monitoring devices, integration of telemedicine and remote patient monitoring, growth in cognitive assessment and neurofeedback software, increasing focus on personalized brain disorder treatment, expansion of neuroimaging and data analytics solutions.

Global Brain Disease Device And Software Market Segmentation

1) By Type: Brain Disease Device, Brain Disease Software 2) By Technology: Wearable Technology, Telemedicine Solutions, Artificial Intelligence And Machine Learning, Mobile Health Applications, Neuroimaging Technologies 3) By Application: Alzheimer’s Disease, Parkinson’s Disease, Epilepsy, Other Applications 4) By End-User: Hospitals And Clinics, Home Care Settings, Rehabilitation Centers, Research and Academic Institutions, Diagnostic Laboratories Subsegments: 1) By Brain Disease Device: Neurostimulation Devices, Brain Imaging Devices, Brain Monitoring Devices, Brain-Computer Interface Devices, Neurorehabilitation Devices 2) By Brain Disease Software: Brain Imaging Analysis Software, Cognitive Assessment Software, Neurofeedback Software, Brain Data Management Software, Neurological Disorder Diagnostic Software

What Is The Driver Of The Brain Disease Device And Software Market?

The increasing prevalence of neurological disorders is expected to propel the growth of the brain disease device and software market going forward. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, leading to a range of symptoms including cognitive, motor, and sensory impairments. The increasing prevalence of neurological disorders is linked to the aging global population, as aging gradually impairs neuronal function, reduces brain plasticity, and elevates oxidative stress, contributing to the development and progression of these conditions. Brain disease devices and software help neurological disorder management by enabling early diagnosis and continuous monitoring. They support timely intervention through advanced AI and data analytics, improving patient care and treatment outcomes. For instance, in July 2024, according to the National Health Service, a UK-based government agency, there were 487,432 patients diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, an increase of 3,155 cases compared to May 31, 2024. Therefore, the increasing prevalence of neurological disorders is driving the growth of the brain disease device and software industry.

Key Players In The Global Brain Disease Device And Software Market

Major companies operating in the brain disease device and software market are Medtronic plc, Insightec Ltd., Cadwell Industries Inc., NeuroPace Inc., Synchron Inc., Compumedics Ltd., Neuronetics Inc., BrainsWay Ltd., The Magstim Company Ltd., Paradromics Inc., Linus Health Inc., MagVenture A/S, Neurophet Inc., Neuroelectrics Corporation, BrainScope Company Inc, Blackrock Neurotech LLC, Neurable Inc., NeuroSigma Inc., Cognixion Inc., Brightmind.AI

Global Brain Disease Device And Software Market Trends and Insights

Major companies operating in the brain disease device and software market are focusing on leveraging innovative technologies, such as artificial intelligence (AI)-driven brain imaging analytics, to enhance early and accurate detection, monitoring, and management of neurodegenerative conditions like Alzheimer’s disease and dementia. Artificial intelligence-driven brain imaging analytics involves advanced software platforms that apply machine-learning models to MRI and other neuroimaging data to identify subtle microstructural alterations in brain tissue that conventional volumetric imaging may overlook, thereby enabling earlier and more sensitive diagnosis. For instance, in January 2025, Oxford Brain Diagnostics Ltd., a UK-based medtech company, received U.S. Food and Drug Administration (FDA) 510(k) clearance and subsequently launched CDM Insights, a cloud-native software solution based on its proprietary Cortical Disarray Measurement (CDM) technology. The tool analyzes routine 1.5 T and 3 T MRI scans to generate novel measures of cortical thickness and microstructural disarray in grey matter, providing objective, quantifiable indicators of neurodegeneration. Following regulatory approvals, the company initiated commercial rollout across healthcare systems in the US and UK, supporting clinicians in early diagnosis, disease monitoring, and treatment stratification.

What Are Latest Mergers And Acquisitions In The Brain Disease Device And Software Market?

In January 2025, NVIDIA partnered with Synchron Inc. to advance implantable brain-computer interface (BCI) technology using NVIDIA’s Holoscan platform, enabling real-time neural processing and scalable brain-language models. With this partnership, NVIDIA Corporation aims to leverage Synchron’s brain-computer interface platforms to advance AI-driven neural signal processing and real-time analysis, accelerating innovation in next-generation BCI applications. Synchron Inc. is a US-based healthcare technology company, specializes in developing minimally invasive brain-computer interface devices that enable neural signal acquisition and interaction for clinical and research purposes.

Regional Outlook

North America was the largest region in the brain disease device and software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Brain Disease Device And Software Market?

The brain disease device and software market consists of revenues earned by entities by providing services such as brain mapping services, remote neurological consultation, neurocognitive assessment, neurofeedback therapy, and personalised rehabilitation planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The brain disease devices and software market also includes sales of brain-computer interface systems, intracranial pressure monitors, transcranial magnetic stimulation devices, virtual reality-based rehabilitation kits, and portable electroencephalography headsets. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.